Navigation Links
Otix Global, Inc. Announces Reverse Stock Split

SALT LAKE CITY, March 12 /PRNewswire-FirstCall/ -- Otix Global, Inc. (Nasdaq: OTIX), announced today that its board of directors has authorized a reverse stock split at a 1-for-5 ratio of its outstanding common stock.  The reverse stock split was approved by stockholders at the Company's annual meeting on May 7, 2009, and is expected to be effective on or about March 29, 2010.

As a result of the reverse stock split, every 5 shares of the Company's common stock that are issued will be automatically combined into one issued and outstanding share, with a change in the par value of such shares from $0.001 to $0.005 per share subject to the payout of fractional shares as described below.  The Company's common stock, which is expected to begin trading on a split-adjusted basis when markets open on March 29, 2010, will continue to be traded on the Nasdaq Global Market under the symbol "Otix" on a post-split basis.

As of the effective date, the number of shares of Otix common stock outstanding will be approximately 5,571,761.

The Company has retained its transfer agent, American Stock Transfer, to act as exchange agent.  American Stock Transfer will manage the exchange of old, pre-reverse stock split shares for new post-split shares.  Stockholders of record as of the effective date will receive a letter of transmittal providing instruction for the exchange of their shares as soon as practicable following the reverse stock split.  Stockholders who hold their shares in "street name" will be contacted by their banks or brokers with any instructions.

No fractional shares will be issued as a result of the reverse stock split.  Fractional shares will be cashed out as follows:

Any cash due to stockholders in exchange for fractional shares will be paid as follows:

  • If a stockholder's shares are held in street name, payment for the fractional shares will be deposited directly into the stockholder's account with the organization holding the stockholder's shares.
  • If the stockholder's shares are registered directly in the stockholder's name, payment for the fractional shares will be made by check, sent to the stockholder directly from American Stock Transfer upon receipt of the properly completed and executed transmittal letter and original stock certificates.

The amount of cash to be paid for fractional shares will be equal to the product obtained by multiplying:

  • The average closing sales price of our common stock as reported by NASDAQ for the four trading days preceding the effective date of the reverse stock split; by
  • The amount of the fractional shares.

Holders of less than five shares of our common stock would be eliminated as a result of the payment for fractional shares in lieu of any fractional share interest in connection with the reverse stock split.

Stockholders will not be entitled to receive interest for the period of time between the reverse stock split and the date the stockholder receives his or her cash payment, if any, in lieu of fractional shares.

About Otix Global

Otix Global designs, develops, manufactures and markets advanced digital hearing aids designed to provide the highest levels of satisfaction for hearing impaired consumers.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined under securities laws. Actual results may differ materially and adversely from those described herein depending on a number of factors but not limited to, the following risks: we cannot anticipate the impact of the reverse stock split on our stock price or our ability to regain compliance with the NASDAQ minimum bid requirements for continued listing; we face aggressive competition in our business; acquisitions could be difficult to integrate and disrupt our current business and therefore may harm our operating results; we may poorly operate newly acquired businesses; our consolidation initiative may not produce the cost savings we anticipate; our new products may not increase sales; we may lose a large customer or suffer a reduction in orders from a large customer; we must have innovative, technologically superior products to compete effectively; our products, due to their complexity, may contain errors or defects that are only discovered after sales by our customers, thus harming our reputation and business; we may have issues with intellectual property; we may trigger a debt covenant default which could impact our working capital and potentially disrupt our operations; and we have important international operations, which expose us to a variety of risks including government reimbursement and foreign currency exchange fluctuations, that could impact sales and operating results. For additional information regarding the risks inherent in our business, please see "Factors That May Affect Future Performance" included in our Annual Report on Form 10-K for the year ended December 31, 2008, and Forms 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009, as filed with the Securities and Exchange Commission.

We undertake no obligation to revise our forward-looking statements to reflect events or circumstances after the date hereof as a result of new information, future events or otherwise.

SOURCE Otix Global, Inc.

Back to top
SOURCE Otix Global, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer
2. TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
3. Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
4. Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process
5. Renhuang Announces Price Increase on Shengmai Granules
6. Lorom West Announces Successful Certification to the ISO 13485: 2003 Quality Management Standard (QMS) for Medical Devices
7. Advanced Life Sciences Announces 2009 Fourth Quarter and Full Year Financial Results
8. OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its ION free Large Diameter Head Dual Mobility Acetabular Cup System
9. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
11. CVS Caremark Corporation Announces Quarterly Dividend
Post Your Comments:
(Date:11/27/2015)... -- --> --> ... potential to save costs, improve treatment quality and accelerate ... exploited as yet. Here, particular emphasis is placed on ... tablet or directly at the patients, bedside. ... -->      (Photo: ) ...
(Date:11/27/2015)... -- Research and Markets ( ) has announced ... 2015-2019" report to their offering. ... the author the present scenario and growth prospects of ... the market size, the report considers revenue generated from ... and copper IUDs. The report forecasts the global intrauterine ...
(Date:11/26/2015)... 26, 2015 Un nuevo enfoque ... para el cáncer avanzado.   --> ... fotodinámica de Bremachlorin para el cáncer avanzado.   ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... . --> Clinical Cancer Research . ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in ... that delves into an array of issues that are presently affecting Americans. Dedicated to ... dialogue, this show is changing the subjects consumers focus on, one episode at a ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men ... prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown ... helped advance the healthcare industry as a whole through their advocacy and professional ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients ... central Michigan, have come together on Thanksgiving Day to share the things that ... viewing on the Serenity Point YouTube channel, patients displayed what they wrote on ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... workshops to discuss bioavailability and the need to integrate dose form selection in ... collaboration with OBN, the membership organization supporting and bringing together the UK’s emerging ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
Breaking Medicine News(10 mins):